Abstract: Provided are compositions and methods for use in selectively killing certain types of bacteria which include: C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. In certain examples, the compositions and methods are used to treat bacteria that infect avian animals. Pharmaceutical formulations containing the polypeptides are provided, as are methods of making the polypeptides using expression vectors. The expression vectors, and cells containing them are included.

Abstract: Provided are compositions and methods for use in selectively killing one or more of C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. Diagnostic approaches are also included by contacting a sample obtained or derived from an animal, with a recombinant polypeptide, and detecting binding of the polypeptide to bacteria in the sample if said bacteria that are bound to the polypeptide are present in the sample. The polypeptide may thus be detectably labeled to produce a detectable signal.

Abstract: Provided are polypeptides and compositions comprising the polypeptides for use in killing and/or inhibiting growth of Gram-negative bacteria, particularly P. aeruginosa. The polypeptides are contiguous polypeptides (lysocins) that contain an engineered bacteriocin segment that can be translocated through an outer membrane channel of the Gram-negative bacteria, such as Domain I of the S-type poycin from P. aeruginosa bacterocin pyocin S2 (PyS2) linked to a lysin catalytic segment that has peptidoglycan (PG) hydrolase activity. The lysin catalytic segment can be a catalytic segment of GN4 lysin or any other lysin catalytic segment or a hydrolytic enzyme thereof that has PG hydrolase activity.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.

Abstract: Provided are methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-negative bacteria, including Klebsiella, Enterobacter, and Pseudomonas, and related conditions. The compositions and methods utilize Klebsiellapneumonia, Enterobacter, and Pseudomonas derived bacteriophage lysins, and variants thereof, including truncations thereof.

Abstract: Provided are compositions and methods for use in selectively killing one or more of C. perfringens, C. sordelli and C. histolyticum. The compositions include lysin PlyCP025, as well as catalytically active fragments thereof, and variants thereof that retain killing activity. Methods for reducing one or more of C. perfringens, C. sordelli or C. histolyticum bacteria are provide and involve contacting such bacteria with a composition that contains PlyCP025 or an enzymatically active fragment or variant thereof, which can be provided as recombinant polypeptides. The composition and methods are useful for human and veterinary purposes. Diagnostic approaches are also included by contacting a sample obtained or derived from an animal, with a recombinant polypeptide, and detecting binding of the polypeptide to bacteria in the sample if said bacteria that are bound to the polypeptide are present in the sample. The polypeptide may thus be detectably labeled to produce a detectable signal.

Abstract: Provided are methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of Gram-negative bacteria, including Pseudomonas, and related conditions. Provided are compositions and methods incorporating and utilizing Pseudomonas aeruginosa derived bacteriophage lysins, and variants thereof, including truncations thereof. Methods for treatment of humans and non-human animals are provided.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.

Abstract: Provided are compositions, methods and kits that are useful for detecting, inhibiting the growth of, and killing bacteria. The compositions include recombinant, chimeric polypeptides that contain at least one immunoglobulin fragment crystallizable region (Fc) segment and at least one additional segment that contains a binding domain that is specific for a bacterial cell wall substrate. The binding domain is one from one or more of a bacterial autolysin, a bacteriophage lysin, a bacteriophage tail or tail fiber, or a bacteriocin. Method of using the polypeptides for detecting, inhibiting the growth of, and killing bacteria are provided and involve contacting bacteria with the polypeptides. Methods of making the polypeptides include expressing the polypeptides in cells, and separating the polypeptides from the cells. Polynucleotides, such as expression vectors, that encode the chimeric polypeptides are also provided.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.

Abstract: Provided are compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including bacilli, and related conditions. The compositions and methods incorporate and utilize Clostridium difficile derived bacteriophage lysins, particularly PlyCD truncations. Methods for treatment of humans and non-human mammals are provided.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.

Abstract: The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to Bacillus anthracis. The disclosure further provides methods and uses thereof.

Abstract: The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to Bacillus anthracis. The disclosure further provides methods and uses thereof.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: Novel bacteriophages of Bacillus anthracis, the nucleic acids of its genome, nucleic acids comprising nucleotide sequences of open reading frames (ORFs) of its genome, and polypeptides encoded by the nucleic acids, are described. Therapeutic and diagnostic compositions, methods and kits related thereto are also provided.